The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Uy Ear - Mizuho - Analyst
: Taking your questions on. So couple of so I'm just following up on the previous question at these sites that enrolled patients previously on the
could you maybe elaborate on or remind us just like were most of these patients referral by physicians? And were there large volumes of patients
with just a few patients at these sites on? Yes. So that's sort of the first questions. I'll ask a second question after. Thanks.
Question: Uy Ear - Mizuho - Analyst
: Okay.
Question: Uy Ear - Mizuho - Analyst
: All right. Thanks. And maybe on more presently, um, could you provide some color on maybe the proportion of patients who have been so far role
in Reliance to and harm? And then maybe relight as well on hand and before and after that, maybe just briefly on Magat on like just tell us help us
think come think about how to model the cadence of spending is it sort of relatively flattish or what it's sort of so down towards the end of the
year? Thanks.
Question: Uy Ear - Mizuho - Analyst
: Very helpful. Thank you, sir.
Question: Andrew Tsai - Jefferies - Analyst
: Yes, good afternoon. Thanks for taking my questions. So first one, I noticed in your prepared remarks, you said how you are monitoring sites in real
time making changes accordingly. So what exactly are you monitoring for and what kinds of changes are you making on a day-to-day kind of basis?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 19, 2024 / 8:30PM, RLMD.OQ - Q4 2023 Relmada Therapeutics Inc Earnings Call
And then secondly, on, are there any learnings or thoughts that you might have on Sage's recent rejection further MDD study and say not study,
but the approval? And if there's any read-through or any lessons learned that you think you could apply to REL 1.17? Thanks.
Question: Andrew Tsai - Jefferies - Analyst
: Perfect on Serg and recently had their own NDA projected for MDD. And I'm just curious if on the reason behind that rejection has any bearing or
read through to your US methadone, basically?
Question: Andrew Tsai - Jefferies - Analyst
: Makes sense. Okay. Thank you very much.
Question: Andrea Tan - Goldman Sachs - Analyst
: Good afternoon. Thanks for taking our questions. On surgery or Andrew, just curious if you're able to share what Reliance to in the relight studies
are powered to detect and And remind us what you're assuming here for placebo response?
Question: Andrea Tan - Goldman Sachs - Analyst
: And then maybe just one quick question on the RALP. a lesson here. Just wanted to confirm which indication you're looking to study this end as
yet?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 19, 2024 / 8:30PM, RLMD.OQ - Q4 2023 Relmada Therapeutics Inc Earnings Call
Question: Andrea Tan - Goldman Sachs - Analyst
: Got it. Maybe just one follow-up there. Have you seen evidence to date pre-clinically that that you are avoiding a loss of muscle from when you've
tracked the weight loss in these rodents?
Question: Andrea Tan - Goldman Sachs - Analyst
: Thanks, everyone.
| 
